We are closer than ever to developing an urgently needed hepatitis C vaccine. But in order to get there we need your help.
Examining feasibility, acceptability, effectiveness and cost-effectiveness of a community-based testing and treatment program for hepatitis C in Myanmar.
The CT2 Study is an effectiveness-implementation hybrid trial assessing the feasibility, acceptability, effectiveness and cost-effectiveness of a community-based testing and treatment program for hepatitis C.
The study sites are in Yangon, Myanmar: Burnet Institute Thingangyun Clinic and Myanmar Liver Foundation Than Sitt Charity Clinic. These two sites serve people who inject drugs and general population respectively.
Each site provides point-of-care hepatitis C testing using rapid diagnostic test for hepatitis C antibody and the GeneXpert HCV VL test for hepatitis C RNA (with result available in under two hours). Participants with chronic hepatitis C virus infection are then offered direct-acting antiviral therapy. Participants’ treatment work-up is conducted by the generalist doctor at the clinic, with hepatologist support available if required.
This study provides the opportunity to treat up to 450 patients for their hepatitis C in primary care; complementing the National Hepatitis Control Program’s QuickStart treatment program in the tertiary hospitals.
The results of this study will inform any potential scale-up of community-based primary care provision of hepatitis C services in Myanmar and other resource-constrained settings.
January 2019 – June 2020.
Completed intensive training 7th to 11th January 2019.
Recruitment started on the 30th of January 2019.
Myanmar Liver Foundation (partner)
Foundation of Innovative and New Diagnostic; Unitaid